PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?
Precipio Inc PRPO
$23.65
▼ -3.35%
($-0.82)
🎈 Low Float
Open
$24.33
Prev Close
$24.47
Day Range
$23.45 – $24.62
52W Range
$16.40 – $33.63
Market Cap
$42.34M
Beta
1.46
EPS (TTM)
$-0.68
📋 Company Profile
| Industry | Health Care |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2000-07-18 |
| Shares Out. | 1,790,000 |
| Website | precipiodx.com/ ↗ |
| Phone | 12037877888 |
| Employees | 71 |
| Revenue | $7.0M |
| Gross Profit | $3.1M |
| Net Income | -$219,000 |
| Free Cash Flow | $789,000 |
| Total Assets | $21.3M |
| Total Liabilities | $6.6M |
| Equity | $14.8M |
About Precipio Inc
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.
Precipio Inc is a publicly traded company under the ticker symbol PRPO on the NASDAQ NMS - GLOBAL MARKET, operating in the Health Care industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2024-06-01)